Published Date: 29 Apr 2024
Standard prophylactic factor IX was found to be noninferior to one dose of fidanacogene elaparvovec.
Read Full News1.
A new therapeutic approach could help tackle radiation resistance in childhood brain tumors
2.
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer
3.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
4.
After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.
5.
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors
1.
Unlocking the Secrets of Improved Ovarian Cancer Survival Rates
2.
The Statistical Evolution of Cancer Staging and Its Precision Impact on Prognosis and Therapy in Cancer Staging 2025
3.
Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production
4.
Florinef: Understanding Its Uses and Side Effects
5.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation